Chemed (CHE)
(Delayed Data from NYSE)
$582.06 USD
-3.21 (-0.55%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $582.47 +0.41 (0.07%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth C Momentum B VGM
Price, Consensus and EPS Surprise
CHE 582.06 -3.21(-0.55%)
Will CHE be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CHE based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CHE
Why Chemed (CHE) is a Top Growth Stock for the Long-Term
Why Chemed (CHE) is a Top Growth Stock for the Long-Term
CHE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should iShares MSCI USA Small-Cap Min Vol Factor ETF (SMMV) Be on Your Investing Radar?
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
Other News for CHE
Chemed management to meet with Oppenheimer
Chemed management to meet with Oppenheimer
These are the mid-caps that could perform best during ‘downturn’ regimes – BofA
Chemed To Report Third-Quarter 2024 Earnings October 29, Related Conference Call To Be Held On October 30
Chemed management to meet with Oppenheimer